Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;2(1):22-30.
doi: 10.3978/j.issn.2304-3881.2012.11.03.

Liver transplantation for hepatocellular carcinoma

Affiliations
Review

Liver transplantation for hepatocellular carcinoma

Jerome Byam et al. Hepatobiliary Surg Nutr. 2013 Feb.

Abstract

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and is considered an aggressive tumor with mean survival estimated between 6 and 20 months. Hepatitis B and C are the most common etiologies. Pathological, laboratory and radiologic imaging all aid in diagnosis but much controversy exists in the utilization of any given modality. Many treatment options exist for management of HCC, each has its own limitation. Liver transplantation offers the most reasonable expectation for curative treatment while simultaneously removing the burden of the diseased liver. Still, advancements in the field have thus far not yet matched its potential, although new immunosuppressive and chemotherapy regimen may allow transplantation to push the envelope once again.

Keywords: Hepatocellular carcinoma; heptatoma; liver transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Prevelence of Hepatitis B (http://www.hepbnet.org/about.asp); B. Prevelence of Hepatitis C (http://relief.unboundmedicine.com/relief/ub/view/cdc-yellow-book/204050/all/Hepatitis_C)

References

    1. Society AC. What are the key statistics about liver cancer. 2012 [cited 2012 October 21, 2012]; Available online: http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what...
    1. Ranieri G, Gadaleta-Caldarola G, Goffredo V, et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 2012;19:938-44 - PubMed
    1. Kudo M. Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets. 2012 [Epub ahead of print] - PubMed
    1. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10:1301-11 - PubMed
    1. Chakrabarty SP, Murray JM. Modelling hepatitis C virus infection and the development of hepatocellular carcinoma. J Theor Biol 2012;305:24-9 - PubMed